Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.oraloncology.2008.02.003 | DOI Listing |
Chin Med J (Engl)
January 2025
Department of Surgery, University of Virginia, Charlottesville, Virginia 22903, USA.
Dig Liver Dis
January 2025
NEUROFARBA Department, University of Florence, viale Gaetano Pieraccini 6, 50139 Firenze, Italy; Meyer Children's Hospital IRCCS, viale Gaetano Pieraccini 24, 50139 Firenze, Italy.
Br J Anaesth
January 2025
Department of Anaesthesia, Monash Medical Centre, Melbourne, VIC, Australia.
Food Chem
January 2025
Poznań University of Technology, Institute of Chemistry and Technical Electrochemistry, Berdychowo 4, 60-965 Poznań, Poland. Electronic address:
Catechins, due to their high antioxidant capacity, are ones of the most common ingredients of human diet (e.g. tea, fruits, cacao) of the well-known health benefit properties.
View Article and Find Full Text PDFAm J Cardiovasc Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!